000 04372nam a22006015i 4500
001 978-3-031-32815-2
003 DE-He213
005 20240207153729.0
007 cr nn 008mamaa
008 231012s2023 sz | s |||| 0|eng d
020 _a9783031328152
_9978-3-031-32815-2
050 4 _aRC321-580
072 7 _aPSAN
_2bicssc
072 7 _aMED057000
_2bisacsh
072 7 _aPSAN
_2thema
082 0 4 _a612.8
_223
245 1 0 _aBiomarkers for Huntington's Disease
_h[electronic resource] :
_bImproving Clinical Outcomes /
_cedited by Elizabeth A. Thomas, Georgia M. Parkin.
250 _a1st ed. 2023.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2023.
300 _aXVI, 475 p. 42 illus., 39 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aContemporary Clinical Neuroscience,
_x2627-5341
500 _aAcceso multiusuario
505 0 _aMolecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers -- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics -- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers -- MRI - non-invasive functional MRI measures -- The evolution of clinical trial methodology.-Digital biomarkers -- The future of telehealth -- Summary and future trends.
520 _aHuntington's disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.
541 _fUABC ;
_cPerpetuidad
650 0 _aNeurosciences.
650 0 _aNeurology .
650 0 _aNeurophysiology.
650 0 _aNeuropharmacology.
650 1 4 _aNeuroscience.
650 2 4 _aNeurology.
650 2 4 _aNeurophysiology.
650 2 4 _aNeuropharmacology.
700 1 _aThomas, Elizabeth A.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aParkin, Georgia M.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031328145
776 0 8 _iPrinted edition:
_z9783031328169
776 0 8 _iPrinted edition:
_z9783031328176
830 0 _aContemporary Clinical Neuroscience,
_x2627-5341
856 4 0 _zLibro electrónico
_uhttp://libcon.rec.uabc.mx:2048/login?url=https://doi.org/10.1007/978-3-031-32815-2
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c262994
_d262993